Compile Data Set for Download or QSAR
maximum 50k data
Found 4814 with Last Name = 'severance' and Initial = 'dl'
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Integral Biosciences

Curated by ChEMBL
LigandPNGBDBM50205634(CHEMBL3933203)
Affinity DataIC50:  27nMAssay Description:Inhibition of human wild type EZH2 using histone H3 as substrate after 1 hr in presence of 3H-SAM by filter paper detection analysisMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421878((S)-7-(2-(4-(4-(3-methyl-1,2,4-oxadiazol-5-yl)phen...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421880((S)-2-(3-Cyclopropyl-1H-indazol-5-yl)-7-(2-(4-(4-(...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421881((S)-7-(2-(4-(4-(1-Ethyl-1H-1,2,4-triazol-3-yl)phen...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421882((S)-7-(2-(4-(4-(1-(2-Hydroxyethyl)-1H-1,2,4-triazo...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421883((S)-7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)phe...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421884((S)-2-(3-(6-Isopropoxypyridin-3-yl)-1H-indazol-5-y...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421885((S)-7-(2-(4-(4-(1-Cyclopropyl-1H-1,2,4-triazol-3-y...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421886((S)-5-(7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421887((S)-2-(3-(Difluoromethyl)-1H-indazol-5-yl)-7-(2-(4...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421889((S)-2-(3-(6-Isopropoxypyridin-3-yl)-1H-indazol-5-y...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421890((S)-7-(2-(4-(2-Fluoro-4-(1-methyl-1H-1,2,4-triazol...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421891((S)-7-(2-(4-(3-Fluoro-4-(1-methyl-1H-1,2,4-triazol...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421892((S)-7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)phe...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421893((S)-7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)phe...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421885((S)-7-(2-(4-(4-(1-Cyclopropyl-1H-1,2,4-triazol-3-y...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421886((S)-5-(7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421887((S)-2-(3-(Difluoromethyl)-1H-indazol-5-yl)-7-(2-(4...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421889((S)-2-(3-(6-Isopropoxypyridin-3-yl)-1H-indazol-5-y...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421890((S)-7-(2-(4-(2-Fluoro-4-(1-methyl-1H-1,2,4-triazol...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421891((S)-7-(2-(4-(3-Fluoro-4-(1-methyl-1H-1,2,4-triazol...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421892((S)-7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)phe...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421893((S)-7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)phe...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421835(US10493060, Example GDC-0994)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421835(US10493060, Example GDC-0994)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421836(US10493060, Example BVD-523)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421836(US10493060, Example BVD-523)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421837(US10493060, Example SCH772984)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421837(US10493060, Example SCH772984)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421838(2-(3-(6-Isopropoxypyridin-3-yl)-1H-indazol-5-yl)-7...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421838(2-(3-(6-Isopropoxypyridin-3-yl)-1H-indazol-5-yl)-7...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421840(2-(3-(6-Isopropoxypyridin-3-yl)-1H-indazol-5-yl)-7...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421840(2-(3-(6-Isopropoxypyridin-3-yl)-1H-indazol-5-yl)-7...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421843(7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)phenyl)...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421843(7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)phenyl)...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421844(7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)phenyl)...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421844(7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)phenyl)...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421845((S)-7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)phe...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421845((S)-7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)phe...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421846((R)-7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)phe...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421847((S)-2-(3-(6-Isopropoxypyridin-3-yl)-1H-indazol-5-y...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421847((S)-2-(3-(6-Isopropoxypyridin-3-yl)-1H-indazol-5-y...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421849((5S)-7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)ph...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421849((5S)-7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)ph...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421851((S)-7-(2-(4-(4-(1H-1,2,3-Triazol-1-yl)phenyl)-3,6-...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421851((S)-7-(2-(4-(4-(1H-1,2,3-Triazol-1-yl)phenyl)-3,6-...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421852((S)-2-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-y...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421852((S)-2-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-y...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421853((S)-2-(3-(6-Isopropoxypyridin-3-yl)-1H-indazol-5-y...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421853((S)-2-(3-(6-Isopropoxypyridin-3-yl)-1H-indazol-5-y...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 4814 total ) | Next | Last >>
Jump to: